Oncobiologics Inc (NYSE:ONS) SVP Scott A. Gangloff sold 37,369 shares of the stock in a transaction that occurred on Friday, November 11th. The stock was sold at an average price of $3.75, for a total value of $140,133.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Oncobiologics Inc (NYSE:ONS) opened at 3.95 on Wednesday. The stock’s market capitalization is $90.07 million. The stock has a 50 day moving average price of $4.08 and a 200 day moving average price of $3.94. Oncobiologics Inc has a 52 week low of $3.04 and a 52 week high of $5.49.

Oncobiologics Company Profile

Oncobiologics, Inc is a United States-based biosimilar company. The Company is focused on monoclonal antibodies (mAbs), in the therapeutic areas of immunology and oncology. The Company’s BioSymphony Platform addresses various challenges in developing and commercializing mAb biosimilars. The Company is working on eight biosimilar candidates, namely, ONS-3010, ONS-1045, ONS-1050, ONS-1055, ONS-4010, ONS-3030, ONS-3035 and ONS-3040.

5 Day Chart for NYSE:ONS

Receive News & Stock Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related stocks with our FREE daily email newsletter.